Please Wait
Applying Filters...
menu
    • menu
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Data Compilation
    #PharmaFlow

    Pipeline Prospector 2024 highlights: Rise in new breed of biotechs with maiden approvals; GLP-1 meds show promise beyond obesity

    Stock Recap
    #PipelineProspector

    Menu

    Naltrexone [USAN:INN:BAN]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,879Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/01/2025 Noramco
    U.S.A
    		 NORAMCO LLC 22992 NALTREXONE DRUG SUBSTANCE 2009-07-28 Active II Complete 2016-04-23 2016-04-07
    28/01/2025 CHONGQING LAND TOWER PHARMACEUTICAL CO
    China
    		 CHONGQING LAND TOWER PHARMACEUTICAL CO LTD 29619 NALTREXONE 2015-09-30 Active II Complete 2016-01-12 2015-09-22